Summary
Stryker Corporation (SYK) reported solid top-line growth in the third quarter and first nine months of 2011, with net sales increasing by 14.9% and 14.4% respectively, driven by a combination of organic growth, favorable foreign currency exchange rates, and significant contributions from acquisitions, most notably the Neurovascular division. Despite the revenue growth, net earnings saw a slight decline of 3.0% and 3.5% for the respective periods, primarily due to increased cost of sales related to inventory step-ups from recent acquisitions and acquisition/integration-related charges. Excluding these one-time impacts, adjusted net earnings showed a healthy increase, indicating underlying operational strength. The company also continued its commitment to shareholder returns through dividends and share repurchases, while maintaining a strong liquidity position with substantial borrowing capacity.
Financial Highlights
52 data points| Revenue | $2.03B |
| Cost of Revenue | $669.00M |
| Gross Profit | $1.36B |
| R&D Expenses | $122.00M |
| SG&A Expenses | $765.00M |
| Operating Expenses | $918.00M |
| Operating Income | $444.00M |
| Net Income | $327.00M |
| EPS (Basic) | $0.85 |
| EPS (Diluted) | $0.84 |
| Shares Outstanding (Basic) | 386.00M |
| Shares Outstanding (Diluted) | 388.40M |
Key Highlights
- 1Net sales increased by 14.9% to $2.03 billion for the third quarter and 14.4% to $6.09 billion for the first nine months of 2011, reflecting robust top-line performance.
- 2The Neurotechnology and Spine segment experienced significant growth (45.8% and 48.9% for Q3 and YTD respectively), largely driven by the acquisition of the Neurovascular business.
- 3Acquisitions, including Neurovascular, Orthovita, and Memometal, contributed substantially to revenue growth, accounting for 7.6% and 6.8% of sales increases in the quarter and year-to-date periods, respectively.
- 4While reported net earnings declined slightly, adjusted net earnings (excluding acquisition-related charges and inventory step-ups) grew by 11.0% and 10.4% for the third quarter and nine months, respectively, indicating strong operational performance.
- 5The company repurchased approximately $539 million of its common stock in the first nine months of 2011 and declared quarterly dividends, demonstrating a commitment to shareholder returns.
- 6Cash flow from operating activities for the first nine months was $807 million, though lower than the prior year, the company maintained a strong liquidity position with $1.1 billion in available borrowing capacity.
- 7The company is facing significant tax-related uncertainties and ongoing legal proceedings, particularly concerning cost-sharing arrangements and alleged patent infringements, which could materially impact future results.